中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南

Chinese Clinical Practice Guidelines for transarterial chemoembolization of hepatocellular carcinoma

肝细胞癌(HCC)是起源于肝细胞的恶性肿瘤,中国HCC患者80%发生于乙型肝炎病毒(HBV)感染。HCC通常是一种富血供肿瘤,经动脉化疗栓塞(TACE)治疗一方面阻断肿瘤血供,同时在肿瘤局部聚集高浓度的化疗药物,对肿瘤细胞发挥最大限度的杀伤作用,被公认为HCC非手术治疗最常用方法之一。为此,中国医师协会介入医师分会专家们经讨论提出了《中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南》,内容包括HCC概述、TACE适应证和禁忌证、TACE围手术期处理、TACE手术操作、TACE并发症及其处理、TACE随访和疗效评价以及基于TACE的综合治疗。

Hepatocellular carcinoma(HCC) is a malignant tumor originating from liver cells. Hepatitis B virus(HBV) infection is the cause of HCC in 80% of Chinese patients. Pathologically, HCC is usually a kind of tumor that has rich blood supply. Transarterial chemoembolization(TACE) can block the blood supply of the tumor, besides, high concentration of chemotherapeutic drugs can be accumulated within the tumor,and therefore TACE can kill tumor cells to the maximum extent. TACE has been recognized as one of the most commonly used non-surgical treatments for HCC. In view of this, after in-depth discussion the experts from Chinese College of Interventionalists, Chinese Medical Doctor Association, put forward 《Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma 》. This 《Guidelines》contains the following contents: brief introduction to HCC, indications and contraindications of TACE,perioperative management in TACE treatment, operative procedure of TACE, complications of TACE and their managements, the follow-up observation and therapeutic evaluation of TACE, and TACE-based comprehensive therapy.